Painless future: new members for Board of Directors, funding and clinical results outlook

Schlieren (Zurich), Switzerland, April 27, 2010. The shareholders of Neurotune AG, a Swiss biopharmaceutical company, have elected Dr. Anders Härfstrand and Heinrich Rotach as new members of the board of directors at their annual general assembly on April 21, 2010. Anders Härfstrand is a medical doctor with extensive experience in neuropharmacology and an excellent track record as executive director in the pharmaceutical industry (e.g. Pharmacia, Pfizer, Serono). Heinrich Rotach has extensive experience in the financial industry (e.g. UBS). Neurotune will strongly profit from their knowhow and their standing in the biotech industry and is highly pleased to have them on board.

In March, Neurotune AG has also expanded its capital base by closing a capital raise with its current investors, among them Neurotune´s major shareholder CC Private Equity Partners, as well as additional private investors. This will allow Neurotune to further advance its portfolio in pain and sarcopenia. To this end, the lead compound of Neurotune, NT-11624, is currently in clinical phase IIa in South Africa for antiretroviral treatment-induced pain in AIDS patients. In January 2010, Neurotune had completed recruitment of more than 100 patients. The trial was finished in March 2010. The extraordinarily low drop out rate of 4% clearly indicates that NT-11624 is well tolerated as predicted from previous phase I data. Currently the clinical data of the phase IIa are under statistical analysis with the top line results expected middle of 2010. Furthermore, compassionate use has been requested and granted by the South African regulatory authorities.

ABOUT NEUROTUNE AG
Neurotune was incorporated in January 2005 and has its domicile in Schlieren, Switzerland. Neurotune develops small-molecular drugs and biologicals to treat disorders of the human nervous system, i.e. neuropathic pain and sarcopenia.

ABOUT NEUROPATHIC PAIN
Neuropathic pain is a type of chronic pain. It is a result of damage to the nervous system following infection, disease, injury, and certain medications. Neuropathic pain serves no protective function. Instead of functioning properly to warn of tissue injury, the nervous system malfunctions and becomes the cause of the pain. Neuropathic pain can continue for months or years and is often described as "burning," "electric," "tingling," or "shooting."

Neurotune AG
Dr. Bruno Oesch
CEO
Wagistrasse 27a
8952 Schlieren
Switzerland
Phone +41 44 200 21 95
Fax +41 44 200 21 80
ceo@neurotune.com
www.neurotune.com

Media enquiries
Dr. Holger Bengs
Biotech Consulting
Phone +49 69 6199 4273
Fax +49 69 6199 4249
info@holgerbengs.de

This release was published on openPR.